InSite Vision Incorporated is an ophthalmic product development company that offers ophthalmic pharmaceutical products. The Company's portfolio of products is based on its DuraSite sustained drug delivery technology. The Company's offerings include BromSite and DexaSite. DuraSite sustained drug delivery technology is a synthetic polymer-based formulation to extend the residence time of a drug relative to conventional topical therapies. DuraSite enables topical delivery of a drug as a solution, gel or suspension and can be customized for delivering a variety of drug candidates. The Company is engaged in the research and development and commercial support with the DuraSite drug delivery technology for the following topical products: AzaSite, Besivance, BromSite, DexaSite, AzaSite Plus and ISV-101.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolOTCMKTS:INSV
CUSIPN/A
Phone+1-510-8658800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-1,693.11%
Return on EquityN/A
Return on Assets-608.13%
Miscellaneous
EmployeesN/A
Outstanding Shares131,950,000
Insite Vision (OTCMKTS:INSV) Frequently Asked Questions
What is Insite Vision's stock symbol?
Insite Vision trades on the OTCMKTS under the ticker symbol "INSV."
How were Insite Vision's earnings last quarter?
Insite Vision Inc. (OTCMKTS:INSV) posted its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.03. The company earned $0.39 million during the quarter, compared to analyst estimates of $0.32 million. View Insite Vision's Earnings History.
Has Insite Vision been receiving favorable news coverage?
Media coverage about INSV stock has been trending positive on Friday, according to Accern Sentiment. The research firm scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Insite Vision earned a coverage optimism score of 0.31 on Accern's scale. They also assigned media headlines about the company an impact score of 45.44 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Insite Vision?
Shares of INSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insite Vision's stock price today?
One share of INSV stock can currently be purchased for approximately $0.3470.
How big of a company is Insite Vision?
Insite Vision has a market capitalization of $45.85 million.
How can I contact Insite Vision?
Insite Vision's mailing address is 965 ATLANTIC AVE, ALAMEDA, CA 94501, United States. The company can be reached via phone at +1-510-8658800.
MarketBeat Community Rating for Insite Vision (INSV)
MarketBeat's community ratings are surveys of what our community members think about Insite Vision and other stocks. Vote "Outperform" if you believe INSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
